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1ABSTRACT
All-trans retinoic acid attenuates pulmonary fibrosis through inhibition 
of EphA2-EphrinA1 signal in bleomycin-induced pulmonary fibrosis
mouse model
Ah Young Leem
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Moo Suk Park)
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, 
irreversible, and usually lethal lung disease of unknown pathophysiology. All-trans
retinoic acid (ATRA) is a biologically active metabolite of vitamin A, and is known 
to affect cell differentiation, proliferation, and development. Eph-Ephrin signaling 
mediates various cellular processes including vasculogenesis, angiogenesis, cell 
migration, axon guidance, fluid homeostasis and repair after injury. Only a few 
studies about the effect of ATRA of pulmonary fibrosis have been reported. And the 
2relationship between pulmonary fibrosis and ephrin type-A receptor 2 (EphA2) 
signaling remains unclear. 
Purpose: The aim of this study is to evaluation the role and related signal pathways 
of ATRA in the bleomycin-induced pulmonary fibrosis mouse model and whether 
the mechanism involves the regulation of pre-existing pathways such as and Eph-
Ephrin, PI3k-Akt or Wnt/ß-catenin signaling pathway. 
Methods and Materials: A549 epithelial cells and CCD-11 Lu fibroblast were 
incubated and stimulated with or without ATRA, TGF-β1, and PI3K inhibitor, 
respectively. The levels of Smad2/3 and p-Smad2/3 were analyzed by western 
blotting. For animal models, we studied four experimental mice groups. There were 
PBS control group (PBS exposure), bleomycin + PBS group (PBS instillation after 
bleomycin exposure), bleomycin + ATRA group (peritoneal ATRA injection after 
bleomycin exposure), bleomycin + EphA2 monoclonal antibody group (EphA2
mAb instillation posttreatment after bleomycin exposure). On day 21, eight mice of 
each group were sacrificed. The cell counts and protein concentration in the 
bronchoalveolar lavage fluid (BALF), changes in histopathology, hydroxyproline 
assay, and the expression of several signal pathway proteins including EphA2-
EphrinA1, PI3K-Akt, Wnt/ß-catenin, and cytokine levels were compared among the 
groups. 
Results: In this study, ATRA attenuates PI3K/Akt signaling in fibroblast. We report 
that bleomycin exposure significantly upregulated EphA2 and EphrinA1 expression 
at day 21 after bleomycin exposure. ATRA posttreatment attenuated lung injury 
score and reduced protein concentration of BALF. The expression of EphA2, Ephrin, 
and PI3K 110γ protein was significantly increased after bleomycin instillation, and 
decreased after ATRA posttreatment. ATRA led to a decrease of IL-6 and TNF-α 
3production in the bleomycin + ATRA group compared to the bleomycin + PBS 
group (all, P < 0.05). Inhibiting EphA2 receptor by intranasal EphA2 mAb 
instillation attenuated pulmonary fibrosis, reduced cell counts and protein 
concentration of BALF (all, P < 0.05). Furthermore, bleomycin exposure 
upregulated the expression of Wnt5a and PI3K, and inhibiting EphA2 receptor 
downregulated both of them.
Conclusion: The present data suggest that ATRA attenuated bleomycin-induced 
pulmonary fibrosis, and that it may regulate the EphA2-EphrinA1 signaling and 
PI3K dependent pathway. Furthermore, EphA2 antagonism attenuates the PI3K 
dependent pathway and Wnt/ß-catenin-independent pathway, and decreased
pulmonary fibrosis. Therefore, ATRA and inhibitor for EphA2 may have a 
protective effect in bleomycin-induced pulmonary fibrosis.
----------------------------------------------------------------------------------------------------
Key words: bleomycin, pulmonary fibrosis, All-trans retinoic acid, EphA2 protein, 
PI3K, Wnt
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Ⅰ. INTRODUCTION
Idiopathic pulmonary fibrosis (IPF), the most common form of the idiopathic 
interstitial pneumonias, is a chronic, progressive, irreversible, and usually lethal 
lung disease of unknown cause.1 The cause of IPF is unknown, but it appears to be a 
disorder likely arising from the interplay between environmental and genetic factors. 
It is a progressive and fatal diffuse parenchymal lung disease with unclear 
pathophysiology and there is no clear consensus on treatment. In 2011, the recent 
5American Thoracic Society/European Respiratory Society/Japanese Respiratory 
Society/Latin America Thoracic Association jointly published guidelines based on 
evidence-based idiopathic pulmonary fibrosis (IPF), but in the end still it did not 
give a clear and effective plan of treatment.2
All-trans retinoic acid (ATRA) is a biologically active metabolite of vitamin A. It is 
known to affect cell differentiation, proliferation, and development, and has been 
widely used for differentiating therapy of acute promyelocytic leukemia, with the 
ability to overcome promyelocytic leukemia (PML)/retinoic acid receptor (RAR) 
fusion protein. And, ATRA is used to ameliorate various models of autoimmunity, 
including rheumatoid arthritis, type 1 diabetes, and experimental 
encephalomyelitis.3-5 However, the therapeutic effects of retinoic acid in such 
diseases remain controversial. Some studies considered that ATRA does not prevent 
or ameliorate lung fibrosis.6 But several previous thought that ATRA can reduce the 
pulmonary fibrosis of both in irradiated and bleomycin-treated mouse lung tissues.7-
9 In these studies, ATRA ameliorates pulmonary fibrosis by regulating protein 
kinase C (PKC)-δ/NF-κB, p38MAPK/NF-κB, and TGF-β1/Smad3 pathways in 
mice model.  
On the other hand, recent studies about EphA related pathway have been reported. 
Eph receptors constitute a large family of receptor tyrosine kinases that mediate 
cell-cell communication when engaged by ephrin ligands found on the surfaces of 
naboring cells.10 Menges et al. reported that EphA2 plays an important role in tumor 
suppressor effects by inhibiting downstream MAP kinases and possibly also the PI3 
kinase-Akt pathway.11
Although Eph receptors and ephrins have been studied in the context of embryonic 
development and tumor progression, but only a few studies about lung fibrosis have 
6been reported. Carpenter et al. reported that EphA2 regulates permeability and 
inflammation in the injured lung, and that EphA2 thus contributes to the 
pathophysiology of acute lung injury in bleomycin-induced mice model.12 However, 
the previous studies were mainly focused on early-stage lung injury, not on the 
pulmonary fibrosis. The relationship between pulmonary fibrosis and ephrin type-A 
receptor 2 (EphA2) signaling remains unclear.
The aim of this study is to evaluation the role and related signal pathways of ATRA 
in the bleomycin-induced pulmonary fibrosis mouse model and whether the 
mechanism involves the regulation of pre-existing pathways such as and Eph-
Ephrin, PI3k-Akt or Wnt/ß-catenin signaling pathway. 
Ⅱ. MATERIALS AND METHODS
1. Cell culture 
A. Human epithelial cell line 
A549 epithelial cell line (American Type Culture Collection, Rockville, MD) and 
CCD-11Lu fibroblast cell line (American Type Culture Collection, Rockville, MD) 
were cultured and used for the experiment. 
B. Chemicals and antibodies
TGF-β1 was purchased from Calbiochem (San Diego, CA, USA). Three types of 
retinoic acid including all-trans retinoic acid (ATRA), 9-cis RA, and 13-cis RA 
were from Sigma (St. Louis, MO, USA). Primary antibodies of Smad proteins for 
western blot were obtained from Cell Signaling Technology (Denver, MA, USA) 
7and Zymed (South San Francisco, CA, USA). β-actin was used for negative control 
and obtained from Delta Biolabs (Gilroy, CA, USA). LY294002 (PI3K inhibitor) 
was purchased from Cell Signaling Technology (Beverly, MA, USA). 
C. Cell culture and chemical stimulation
A549 cells were cultured in RPMI 1640 medium (Gibco BRL, Grand Island, NY, 
USA) supplemented with 10% fetal bovine serum (FBS; Gibco BRL). CCD-11Lu 
cells were cultured EMEM medium (Beckton Dickinson & Company, Lincoln Park, 
NJ, USA). Cells were subcultured 2-3 times weekly to maintain a log phase growth 
and incubated at 37  with 5% CO℃ 2 for 24 hours durations.
As a negative control, cells were incubated with only cell culture medium. To test 
the effects of RA on the activation of Smad induced by TGF-β1, A549 cells were 
stimulated as follows: 1) control, 2) TGF-β1, 3) RA, and 4) TGF-β1 in combination 
with RA: pre-stimulated TGF-β1 prior to RA treatment, and 5) TGF-β1 in 
combination with RA: pre-treated RA prior to TGF-β1 stimulation, respectively. 
After stimulation, A549 cells were incubated for 24 hours, and then processed for 
western blot as described below. Beside, to investigate the different effect of TGF-
β1 between A549 cells and CCD-11Lu cells, each cell was pretreated with none or 
PI3K inhibitor. These pretreated cells were stimulated above-mention same methed; 
1) control, 2) TGF-β1, 3) RA, and 4) TGF-β1 in combination with RA: pre-stimulated 
TGF-β1 prior to RA treatment, and 5) TGF-β1 in combination with RA: pre-treated 
RA prior to TGF-β1 stimulation, respectively. 
D. Western blotting analysis
2x106cells were dissolved in 100 mm dish plates and pre-incubated 2 hours with
8RPMI 1640 medium. After 24 hours with or without chemical stimulation, cells 
were washed twice with cold PBS, scraped and solubilized in a RIPA-B buffer 
containing 0.5% nonidet P-40, 20 mM Tris-HCl (pH 8.0), 50 mM NaCl, 50 mM 
NaF, 100 μM Na3VO4, 1 mM DTT, 50 μg/ml PMSF, 20 μg/ml aprotinine, and 20 
μg/ml leupeptine. After 30 minutes in 4 , cell lysates were cleared of debris by ℃
centrifugation with 4 , 12,000 rpm, and 20 minutes. The 20 μg of protein lysates ℃
were applied to the 10% SDS-PAGE gel and transferred to nitrocellulose 
membranes (Amersham Biosciences, Piscataway, NJ, USA). The membranes were 
blocked at room temperature with 5% skim milk in TBST (1X TBS, 0.1% Tween 
20). After washing twice in TBST, the membranes were incubated with the primary 
Smad antibodies for 2 hours at room temperature. The membranes were then 
washed triple times for 10 minutes in TBST, and incubated with the relevant HRP-
conjugated secondary antibodies (1:1000 dilated with 3% BSA in TBST) for 1 hour. 
After washing triple times in TBST, the reactive proteins were visualized by an 
enhanced chemiluminescence (ECL) detection system (Amersham Biosciences, 
Pittsburg, PA, USA).
2. Bleomycin-induced pulmonary fibrosis mouse model 
All animal protocols were approved by the institutional animal care committee of 
the Medical College of Yonsei University (2014-0368). All animal experiments 
were conducted in accordance with the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health. 
Wild type male C57BL/6J mice, 7 weeks of age and weighing 18~22 g were 
purchased from Orient Bio (Sungnam, Republic of Korea). All animals were 
9supplied with food and water and were subjected to a similar day and night light 
cycle.
Thirty two mice were divided to four groups: (A) control group with PBS inhalation
(n = 8), (B) bleomycin-induced pulmonary fibrosis group with PBS posttreatment (n 
= 8), (C) bleomycin-induced pulmonary fibrosis group with ATRA (0.5 mg)
posttreatment (n = 8), (D) bleomycin-induced pulmonary fibrosis group with EphA2 
monoclonal antibody (mAb) posttreatment (n = 8). Additionally, total cell count, 
protein concentration, and lung injury scores of bleomycin-induced pulmonary 
fibrosis group with ATRA (1.0 mg) posttreatment (n = 4) group was compared with 
the results of ATRA (0.5 mg) posttreatment group.  
The experiment was performed by intranasal administration. Mice were lightly 
anesthetized by inhalation of isoflurane (Abbott Laboratories). The mouse was held 
in a supine position with the help of microsyringe (Hamilton Company cat# 7637-
01). We adjusted the rate of release so as to allow the mouse to inhale the solution 
without trying to form bubbles.
50 μl of sterile phosphate-buffered saline (PBS) was administered by intranasal 
instillation for the control group. Except for the control group, bleomycin (Sigma, 
St Louis, MO, USA) 5 U/kg in 50 ul PBS was administered by intranasal instillation. 
As posttreatment, 0.5 mg of ATRA (sigma, St Louis, MO, USA) powder dissolved 
in 0.1 mL DMSO was injected for the bleomycin + ATRA group. Injections were 
repeated 3 times weekly. For the bleomycin + EphA2 mAb group, 4 μg of EphA2 
mAb (R&D Systems, Cat# MAB639) were intranasally administered 3 times 
weekly. 
On day 21, mice of each group were sacrificed. The bronchoalveolar lavage fluid 
(BALF) and lung specimens were collected. 
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A. Analysis of bronchoalveolar lavage fluid (BALF)
21 days after bleomycin/PBS inoculation, all mice were humanely euthanized by 
lethal overdose of xylazine. BAL was performed through a tracheal cannula using 
with a two 1 ml aliquots of sterile saline. The BAL fluid was centrifuged (4˚C, 
1500~5000 rpm, 10 min) and the supernatant was stored at 80°C for further analysis.
The cell pellet was reconstituted in 100 μl PBS and used for quantitative and 
qualitative cell counts. Total cell numbers were counted from each sample using a 
hemocytometer (Marienfield, Germany) according to the manufacturer’s protocol. 
The slide chambers were prepared by inserting slide into frame with Poly-L lysine 
coating up and clamping with clips on either side. 90 μl aliquot of each sample was 
transferred into the slide chambers that were inserted into cytospin with the slide 
facing outward. Spinning was done at 600 rpm for 6 minutes. The slides were 
removed from cytocentrifuge and dried prior to staining. Diff Quick (Sysmex 
corporation) staining was used. The slides were immersed in three Diff Quickfluid 
(Fixative, Solution I, Solution II) for 5 seconds and rinsed with purified water.
The protein content of the BAL supernatant was measured using Coomassie 
Brilliant Blue G-250 technique (Quick StartTM Bradford Protein Assay, US). 25 μl 
of each sample and 200 μl of working reagent were pipetted into a microplate well 
and mixed thoroughly on a plate shaker for 30 seconds. After incubation for 30 min 
at 37°C, the plate was cooled and read at 595 nm by spectrophotometer.
B. Lung tissue harvest and histologic examination 
The right lung was isolated and stored at -80°C prior to protein extraction, after 
flushing the pulmonary vasculature with saline under low pressure. The left lung 
was inflated via the tracheotomy with low-melting point agarose (4%) in PBS at 25 
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cm H2O pressure and until the pleural margins became sharp. The lungs were then 
excised and fixed overnight in 10% formaldehyde in PBS and embedded in paraffin 
for sectioning at 5-μm thickness. Left lung sections were stained with H&E and 
Masson subjectively evaluated under light microscopy. The histopathology was 
reviewed in a blinded manner by two qualified investigators. Five easily identifiable 
pathologic processes were scored by a weighted scale presented in the official ATS 
workshop report.13
C. Hydroxyproline assay
The total collagen content of the left lung was measured using a colorimetric assay 
to determine lung hydroxyproline content. Every 10 mg of lung tissue was
homogenized in 100 μL of distilled water. After that, 100 μL of 12 N hydrochloric 
acid was added, and we hydrolyzed the sample for 3 hours at 120°C. After cooling 
briefly, 5 mg of activated charcoal was added. Then, the sample was centrifuged at 
10,000 x g for 5 minutes at 4 ˚C. The supernatant was collected and transferred to a 
new tube. Hydroxyproline assay kit (Cell biopabs, US) was used for the analysis. 
The results were calculated as μg hydroxyproline per mg. 
D. Western blotting and cytokine ELISA
Frozen right lung were mechanically disrupted using a homogenizer in 
homogenization buffer, PRO-PREPTM Extraction solution (iNtRON 
BIOTECHNOLOGY cat# 17081). The amount of solution is 600 μl per 10mg tissue. 
Cell lysis was induced by incubation for 20-30 min on ice or freezer at -20˚C. The 
samples were centrifuged at 13,000 x g for 30 min at 4˚C. Equal amounts of protein 
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were separated by SDS-PAGE and transferred to nitrocellulose membrane before 
immunoblotting with primary Abs as indicated. Membranes were incubated with 
anti-rabbit or anti-mouse IgG HRP conjugated Abs and developed using Super-
Signal West Pico chemiluminescence detection kit (Pierce). The band images were 
quantified by Alpha Ease FC software (Innotech, version 4.1.0).
The antibodies used in this study included rabbit EphA2 (Thermo Fisher Scientific, 
Germany), goat EphrinA1 (Thermo Fisher Scientific, Germany), rabbit PI3 Kinase 
110γ (Cell Signaling Technologies, Beverly, MA), rabbit α-tubulin (Cell Signaling 
Technologies, Beverly, MA), rabbit phosphate–p70 S6 kinase (Cell Signaling 
Technologies, Beverly, MA), rabbit p70 S6 kinase (Cell Signaling Technologies, 
Beverly, MA), rabbit Wnt5a (Cell Signaling Technologies, Beverly, MA). The 
image densities were measured with NIH Image J for semiquantitative comparison.
Measurement of keratinocyte chemoattractant (KC/CXCL1), macrophage 
inflammatory protein 2 (MIP-2), interleukin (IL)-1ß, IL-6, and tumor necrosis 
factor-α (TNF-α) were performed on whole-lung homogenates using quantified 
EILSA kits (MILLIPLEXMAG Mouse Cytokine/Chemokine kit from Millipore, 
Billerica, MA, USA). 
3. Statistical analysis 
Statistical analysis was performed using Prism 5.0 (Graphpad Software, Durham, 
NC). The group comparisons were performed with an unpaired student t test or 
ANOVA with Bonferroni multiple comparisons tests. Data are expressed as means ± 
SD for each group. Differences were considered significant at P <0.05.
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III. RESULTS
1. Fibroblast growth patterns differ from the epithelial cell when treated with ATRA 
at suppression of PI3K signaling 
Fibroblast growth differs compared with epithelial cells when treated with ATRA at 
10-6 M and / or suppression of PI3K signaling with its specific inhitbitor LY294002. 
Both in epithelial cell and fibroblast, relative expression of p-Smad2 and p-Smad3 
were increased with TGF-β alone. Compared with TGF-β alone group, relative 
expression of p-Smad2 and p-Smad3 were decreased significantly with TGF-β and 
ATRA (Figure 1, 2). Relative expression of p-Smad2 and p-Smad3 in TGF-β alone 
group were decreased when treated with PI3K inhibitor (LY294002) in epithelial 
cell (Figure 1). However, it was not in fibroblast. (Figure 2)
14
Figure 1. The expression of p-Smad2 and p-Smad3 with or without PI3K inhibitor 
(LY294002) in epithelial cells. *P < 0.05, **P < 0.01, ***P < 0.001.
15
Figure 2. The expression of p-Smad2 and p-Smad3 with or without PI3K inhibitor 
(LY294002) in fibroblast. *P < 0.05, **P < 0.01, ***P < 0.001.
2. ATRA attenuates PI3K/Akt signaling in fibroblast 
Fibroblast growth differs compared with epithelial cells when treated with ATRA at 
10-6 M. In epithelial cell, relative expression of p-Akt was not significantly 
16
decreased with TGF-β and ATRA group compared with TGF-β alone group.
However, it was significantly decreased with TGF-β and ATRA group compared 
with TGF-β alone group (Figure 3). 
Figure 3. The expression of p-Akt with in (a) epithelial cell and (b) fibroblast. *P < 
0.05, **P < 0.01, ***P < 0.001.
3. ATRA dose-dependently attenuates bleomycin-induced lung injury
We sought to determine whether ATRA dose dependently attenuates lung injury in 
bleomycin-induced pulmonary fibrosis mouse model. 
As shown in Figure 4, bleomycin caused pulmonary fibrosis, as demonstrated by a 
significant increase in concentration of total protein (PBS control group: 0.09 ± 0.01 
mg/ml, bleomycin + PBS group: 1.19 ± 0.27 mg/ml, all P < 0.05) and total cell 
count (PBS control group: 58.63 x 104 ± 13.42 x 104, bleomycin + PBS group: 
384.10 x 104 ± 76.98 x 104, all P < 0.05) in BALF. Furthermore, histologic 
examination of the lungs of mice that received ATRA in addition to bleomycin 
instillation revealed a significant decrease in lung injury score compared with mice 
that received bleomycin and PBS posttreatment (bleomycin + PBS group: 70.50 ± 
17
3.56, bleomycin + ATRA 0.5 mg group: 38.58 ± 3.91, bleomycin + ATRA 1.0 mg 
group: 29.45 ± 2.14 at day 21, all P < 0.05). ATRA posttreatment (0.5 mg and 1 mg)
decreased in concentration of total protein in BALF compared with PBS control 
group. Compared with ATRA 0.5 mg group, total cell count was significantly 
decreased in ATRA 1 mg group. However, total protein and lung injury score were 
not significantly decreased in ATRA 1 mg group, compared with ATRA 0.5 mg 
group (Figure 4). 
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Figure 4. ATRA attenuates bleomycin-induced bleomycin-induced lung injury 
dose-independently at 21 days. (a) Total bronchoalveolar lavage fluid (BALF) cell 
counts. (b) Total BALF protein concentration. (c) The lung injury scores. *P < 0.05, 
**P < 0.01, ***P < 0.001.
4. ATRA and EphA2 antagonist attenuate bleomycin-induced lung injury and 
fibrosis
After finding that bleomycin-induced lung injury was associated with the increased 
expression of EphA2 and Ephrin A1 in the lung, we sougt to determine whether 
EphA2 contributes to pulmonary fibrosis by verifying the effects of EphA2 mAb 
posttreatment. 
As shown in Figure 2, bleomycin caused pulmonary fibrosis, as demonstrated by a 
significant increase in concentration of total protein and total cell count in BALF. 
ATRA posttreatment decreased in concentration of total protein in BALF compared 
with PBS control group. EphA2 mAb posttreatment resulted in significant reduction 
in concentration of both total protein and total cell counts in BALF compared with 
PBS posttreatment after bleomycin instillation. Also, histologic examination of the 
lungs of mice that received ATRA and EphA2 mAb in addition to bleomycin 
instillation revealed a significant decrease in lung injury score compared with mice 
that received bleomycin and PBS posttreatment (bleomycin + PBS group: 70.50 ± 
3.56, bleomycin + ATRA group: 38.58 ± 3.91, bleomycin + EphA2 mAb group: 
47.64 ± 3.68 at day 21, all P < 0.05). The histologic changes are shown by 
hematoxylin and eosin and Masson staining. Pulmonary structure was clear, and 
inflammatory cells and collagen deposition did not exist in pulmonary alveoli in the 
19
PBS control group. Hematoxylin and eosin staining showed the structure of lung 
tissue disordered, pulmonary interalveolar septa thickened and infiltrated by 
inflammatory cells, with collagen depositions in the interstitium, and a large number 
of alveolar collapsed and consolidated in the bleomycin group. Masson staining 
showed that fibroblasts and collagen matrix significantly increased, and the 
formation of fibrosis lesions with cord-like distribution in bleomycin group. 
Alveolitis and the pulmonary fibrosis were reduced in the ATRA group and EphA2 
mAb group as compared with the bleomycin group. Furthermore, in hydroxyproline 
assay, both ATRA and EphA2 mAb decreased hydroxyproline content compared 
with PBS posttreatment after bleomycin instillation. 
20
(e)
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(f)
Figure 5. ATRA and EphA2 mAb attenuate bleomycin-induced pulmonary fibrosis
at 21 days. (a) Total bronchoalveolar lavage fluid (BALF) cell counts. (b) Total 
BALF protein concentration. (c) The lung injury scores. (d) hydroxyproline assay. 
(e) The histologic changes are shown by hematoxylin and eosin staining. (f) The 
histologic changes are shown by Masson staining. *P < 0.05, **P < 0.01, ***P < 
0.001.
5. Bleomycin upregulates EphA2 receptor and its ligand Ephrin A1 expression
As, measured by western blotting, the expression of EphA2 protein and EphrinA1 
protein in lung tissue was increased after bleomycin instillation (EphA2: 1.38-fold, 
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EphrinA1: 1.21-fold), compared with PBS control at day 21 (Figure 1). Furthermore, 
increased expression of EphA2 and EphrinA1 in the lung were inhibited by ATRA 
posttreatment (Figure 6).
Figure 6-1. The expression of EphA2 and EphrinA1 protein in lung lysates, as 
shown by Western blots and densitometry. (a) western blots. (b) densitometry of 
EphA2. (c) densitometry of EphrinA1. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 6-2. The expression of EphA2 and EphrinA1 protein in lung lysates, as 
shown by Western blots and densitometry (ATRA 1mg posttreatment). (a) western 
blots. (b) densitometry of EphA2. (c) densitometry of EphrinA1. *P < 0.05, **P < 
0.01, ***P < 0.001.
6. ATRA attenuates bleomycin-induced pulmonary fibrosis via downregulating 
EphA2-EphrinA1 and PI3K-Akt pathway 
As, mentioned above, measured by western blotting, increased expression of EphA2 
protein and EphrinA1 protein in lung tissue was increased after bleomycin 
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instillation was decreased by ATRA treatment (Figure 6). 
Given the protective effect of ATRA in bleomycin induced lung injury, we 
wondered whether the mechanism involves the regulation of PI3K dependent
signaling. To answer this question, the expression of PI3K 110γ was measured in all
groups. 
As shown in Figure 7-1, compared to the PBS control group, the bleomycin + PBS
group showed significantly increased PI3K 110γ (PI3K 110: 1.85-fold). After ATRA 
posttreatment (0.5mg), the expression of PI3K 110γ was reduced. Futhermore, ther 
expression of Akt was significantly decreased after ATRA posttreatment (1.0mg) 
(Figure 7-2). It is showing that PI3K-Akt signaling is involved in bleomycin-
induced pulmonary fibrosis. ATRA attenuated bleomycin-induced pulmonary 
fibrosis via regulation of PI3K-Akt pathway. 
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Figure 7-1. The expression of PI3K 110γ protein in lung lysates, as shown by (a) 
Western blots. (b) densitometry of PI3K 110 γ. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 7-2. The expression of PI3K 110γ protein in lung lysates, as shown by (a) 
Western blots. (b) densitometry of PI3K 110 γ (ATRA 1mg posttreatment). *P <
0.05, **P < 0.01, ***P < 0.001.
7. Bleomycin upregulates Wnt and PI3K signaling pathway via EphA2 activation.
After finding that bleomycin-induced lung injury was decreased by EphA2 
antagonism, we wondered whether inhibiting the EphA2-EphrinA1 signaling had an 
effect on the existing signal pathways. To answer this question, the expression of 
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various proteins in the lung tissue was measured in PBS group, bleomycin + PBS 
group, bleomycin + ATRA group, and bleomycin + EphA2 mAb group. 
As shown in Figure 3, compared with the PBS control group, the bleomycin + PBS 
group showed significantly increased PI3K 110γ. After ATRA posttreatment, the 
expression of PI3K 110γ was reduced. EphA2 mAb seemed to attenuate bleomycin-
induced pulmonary fibrosis via regulation of PI3K dependent step.
As shown in Figure 8, compared with the PBS control group, the bleomycin + PBS 
group showed significantly increased Wnt5a. However, β-catenin protein was not 
expressed in the bleomycin group. After EphA2 mAb posttreatment, the expression 
of Wnt5a was reduced significantly, showing that EphA2 signaling is involved in 
bleomycin-induced activation of Wnt/β-catenin-independent signaling pathway.
Inhibiting the EphA2-EphrinA1 signaling had no significant effect on expression of 
the proteins related to other signaling pathways, such as phosphate-S6K (data not 
shown). 
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Figure 8. The expression of Wnt5a protein in lung lysates, as shown by (a) Western 
blots and (b) densitometry. *P < 0.05, **P < 0.01, ***P < 0.001.
8. ATRA attenuates bleomycin-induced pulmonary fibrosis via decreasing IL-6 and 
TNF-α
To determine whether ATRA and EphA2 mAb have a protective function in 
inflammatory response, we assessed the cytokine levels (IL-1ß, IL-6, KC, MIP-2, 
and TNF-α) at day 21 by ELISA. IL-6 and TNF-α expression were significantly 
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increased in bleomycin-induced pulmonary fibrosis. ATRA led to a decrease of IL-6 
and TNF-α production in the bleomycin + ATRA group compared to the bleomycin 
+ PBS group (Figure 9).
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Figure 9. The expression of cytokines (IL-1ß, IL-6, KC, MIP-2, and TNF-α) in 
response to ATRA and EphA2 mAb pretreatment in a bleomycin-induced lung 
fibrosis model.
IV. DISCUSSION
Although pulmonary fibrosis accounts for significant morbidity and mortality in 
critically ill patients, there are no specific effective therapies. So, it is important to 
find a therapeutic target and verify the effectiveness of related treatment in 
pulmonary fibrosis. 
In this study, both of ATRA and EphA2 contributed to the pathogenesis in 
bleomycin-induced pulmonary fibrosis of mice. ATRA attenuated bleomycin-
induced pulmonary fibrosis. The expression of EphA2, EphrinA1, and PI3K protein 
was significantly increased after bleomycin instillation, and decreased after ATRA 
posttreatment. Both the expressions of EphA2 receptor and the ligand EphrinA1
were increased in the bleomycin-induced pulmonary fibrosis. Also, blocking the 
activation of EphA2 receptor by EphA2 mAb ameliorates fibrotic changes 
associated with lung injury. Furthermore, bleomycin exposure upregulated the 
expression of Wnt5a and PI3K, and inhibiting EphA2 receptor downregulated both 
of them. In the cytokine assay, ATRA led to a decrease of IL-6 and TNF-α 
production.
The results of ATRA posttreatment group in this study were similar to previous 
studies of mice model. In the study of Tabata et al. ATRA could reduce the 
pulmonary fibrosis of both in irradiated and bleomycin-treated mouse lung tissues.7
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They found that ATRA reduced irradiation-induced IL-6 production through the 
protein kinase C (PKC)-δ/NF-κB pathway, and inhibited irradiation-induced TGF-
β1 production through the p38MAPK/NF-κB pathway, resulting in the inhibition of 
cell differentiation and collagen synthesis. In another study of Tabata et al., ATRA 
reduced irradiation-induced production of both IL-6 receptor (IL-6R) and its 
receptors in the lung fibroblasts and IL-6-dependent cell growth, and also directly 
inhibited the proliferation of lung fibroblasts after irradiation as well as anti-human 
IL-6R antibodies.14 Dong et al. reported that ATRA may ease the bleomycin-
induced pulmonary fibrosis by inhibiting the expression of IL-6 and TGF-β, shifting 
the regulatory T/T-helper 17 (Treg/Th17) ratio and reducing the secretion of IL-17A 
in mice model.8 The study of Song et al. showed that ATRA ameliorates bleomycin-
induced lung fibrosis by downregulating the TGF-β1/Smad3 signaling pathway.9
Consistent with these studies, ATRA decreased bleomycin-induced pulmonary 
fibrosis in the current study. Similar to the results of Tabata et al.14, ATRA reduced 
IL-6 expression of lung. Compared to previous researches which studied mice 
model of 4 weeks after the administration of bleomycin, the sacrifice time (3 weeks)
of this study was earlier than in previous studies. Furthermore, this study suggest 
that ATRA attenuated bleomycin-induced pulmonary fibrosis via regulate the 
EphA2-EphrinA1 signaling and PI3K dependent pathway. 
EphA2 signaling has been studied in angiogenesis, cell migration, fluid homeostasis 
and vascular assembly during early stages of development.10,15 The interaction 
between Eph receptor and Ephrin ligand results in modification of cytoskeletal 
proteins and cell surface receptors.10,15 The previous studies found that actin 
cytoskeleton rearrangement may be a key preceding event during the regulation of 
inflammatory responses in various cell populations.16-19 The disruption of 
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endothelial cell junction by EphA2 signaling, allows the passage of fluid, protein 
and inflammatory cells into an injured tissue.20,21 The various evidences suggest that 
EphA2 signaling may an important mediator in inflammation and injury.12,22-24
There are several studies demonstrate that EphA2 contributes to the pathogenesis in 
acute lung injury. In rats exposed to viral respiratory infection and hypoxia, EphA2 
expression is markedly upregulated and EphA2 antagonism reduced vascular 
leakage in injured lung injury.23 Similarly, in bleomycin-induced lung injury, EphA2 
KO mice were protected from protein extravasation and inflammatory responses.12
Both studies demonstrated that ligand EphrinA1 stimulation of lung endothelial 
EphA2 receptor leads to disruption of endothelial adherens junctions and increased 
permeability. Recently, Hong et al. reported that EphA2 and EphrinA1 were 
upregulated in lipopolysaccharide (LPS)-induced lung injury, and EphA2 
antagonism inhibits the PI3K-Akt pathway and attenuates inflammation.25 However, 
these previous studies were about acute lung injury, not about the pulmonary 
fibrosis model. In this study, the results of EphA2 mAb posttreatment groups were 
similar to previous studies in acute lung injury mice model. In our knowledge, this 
is the first study which investigates the role of EphA2-EphrinA1 signaling pathway 
in the pulmonary fibrosis mice model. 
We found several potential mechanisms by ATRA and EphA2 signaling which can 
be related to the development of bleomycin-induced pulmonary fibrosis (Figure 10).
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Figure 10. The potential mechanisms through which ATRA and EphA2 mAb may 
attenuate development of bleomycin-induced pulmonary fibrosis. 
In this study, blocking EphA2 expression with EphA2 mAb posttreatment after 
bleomycin exposure downregulated the expression of PI3K and Wnt5a compared 
with PBS posttreatment after bleomycin exposure. ATRA treatment decreased the 
expression of EphA2, EphrinA1, and PI3K. The results showed bleomycin induced 
upregulation of PI3K pathway and Wnt/β-catenin-independent pathway were 
mediated through EphA2-EphrinA1 signaling pathway. 
PI3K-Akt signaling pathway has been reported to have an important role in 
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regulating cell proliferation. Bakin et al. reported that PI3K-Akt activation was 
essential to the epithelial mesenchymal transition (EMT) process induced by TGF-
β1 in tumor cell lines.26 Hofmann et al. used TGF-β to stimulate primary 
hepatocytes in mice and demonstrated induction of the EMT and the activation of 
the PI3K-Akt signaling pathway.27 The study of Conte et el. reported that the 
overexpression of PI3K p110γ was observed in IPF lung disuse and fibroblast 
cells.28 Similar to previous studies, the expression of PI3K was increased after 
bleomycin exposure, and decreased with both of ATRA and EphA2 mAb treatment. 
At the biochemical level, the EMT associated with gastrulation is dependent on and 
orchestrated by canonical Wnt signaling.29,30 In previous studies, the Wnt/β-catenin 
signaling pathway has been implicated in the development of experimental and 
human pulmonary fibrosis.31-33 The cell-specific mechanism by which Wnt/β-
catenin signaling exerts its effect on cellular function remains unclear. However, 
crosstalk between TGF-β and Wnt/β-catenin signaling has recently been 
demonstrated as crucial for the EMT and the development of lung fibrosis.34-36 Chen 
et al. reported that inhibiting Wnt/β-catenin signaling could suppress the production 
of the pro-fibrotic cytokines transforming growth factor-β1 (TGF-β1) and fibroblast 
growth factor 2 (FGF-2) in bleomycin-induced fibrotic lung tissue in mice model.35
In this study, the expression of Wnt5a protein was increased with bleomycin 
treatment. However, β-catenin protein was not expressed in the bleomycin group. 
After EphA2 mAb posttreatment, the expression of Wnt5a was reduced significantly, 
showing that EphA2 signaling is involved in bleomycin-induced activation of Wnt/ 
β-catenin-independent signaling pathway.
Previous studies which investigated the significance of EphA2 expression and 
epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric 
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cancer cells have been reported.37 However, there was no study about the 
relationship between EphA2 signaling and Wnt/β-catenin-independent pathway in 
pulmonary fibrosis model.38 Our study provides evidence that bleomycin 
upregulates Wnt/ß-catenin-independent signaling pathway via EphA2 activation.
In this study, we demonstrated that ATRA attenuated bleomycin-induced pulmonary 
fibrosis in mice model, and it may regulate the EphA2-EphrinA1 signaling and 
PI3K dependent pathway. The possible role of ATRA and EphA2 inhibitor as a 
therapeutic agent in pulmonary fibrosis should be verified in human studies. 
V. CONCLUSION
In conclusion, we demonstrate that ATRA attenuated bleomycin-induced pulmonary 
fibrosis, and that it may regulate the EphA2-EphrinA1 signaling and PI3K 
dependent pathway. Furthermore, EphA2 antagonism attenuates inhibits the PI3K 
dependent pathway and Wnt/ß-catenin-independent pathway and attenuates 
pulmonary fibrosis. Therefore, ATRA and inhibitor for EphA2 may have a 
protective effect in bleomycin-induced pulmonary fibrosis. 
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ABSTRACT (IN KOREAN)
bleomycin 으로 유도된 폐 섬유화 쥐 모델에서 EphrinA2-EphrinA1 
신호 전달 체계의 조절을 통한 all-trans retinoic acid의
항섬유화 효과
<지도교수 박무석>
연세대학교 대학원 의학과
임  아  영
배경: 특발성 폐섬유화증은 만성적, 비가역적으로 진행하며, 종종
치명적인 결과를 초래하는 폐 질환으로, 그 병태생리는 명확하게 알려져
있지 않다. All-trans retinoic acid (ATRA)는 비타민 A의 활성화된  
대사물로, 세포의 분화와 증식, 발달과 관계되는 것으로 알려져 있다. 
한편, Eph-Ephrin 신호 전달 체계는 혈관의 형성, 세포의 이동, 세액의
항상성 및 손상 후의 복구를 포함한 다양한 세포 과정을 매개한다. 
폐섬유화에 대한 ATRA의 효과에 대하여 소수의 연구가 보고된 바 있으며, 
폐섬유화외 EphA2 신호 전달 체계의 상관 관계에 대하여는 아직
명확하게 밝혀져 있지 않다. 
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목적: 본 연구에서는 bleomycin으로 유도된 폐섬유화 마우스 모델에서
ATRA 의 역할과, 그 메커니즘이 Eph-Ephrin, PI3K-Akt 혹은 Wnt/ß-
catenin과 같은 기존에 존재하는 신호 전달 체계와 연관되는지를
밝히고자 하였다. 
방법: 세포 실험에서 epithelial cell과 fibroblast를 ATRA, TGF-β1, 
그리고 PI3K 억제제의 유무에 따라 배양하였다. 동물 실험은 대조군, 
bleomycin 그룹, ATRA 그룹, EphA2 monoclonal antibody 그룹의 4 
그룹으로 나누어 진행하였다. 21일째에 각 그룹의 mice로부터
기관지폐포세척액을 획득하여 세포 수와 단백질 농도를 그룹별로 비교, 
분석하였다. 또한 폐 조직을 얻어 각 그룹의 조직학적 변화를 비교하고, 
hydroxyproline assay, EphA2-EphrinA1, PI3K-Akt, Wnt/ß-catenin 신호
전달 체계와 연관된 단백질의 발현 및 cytokine 농도를 각 그룹별로
비교, 분석하였다. 
결과: 본 실험에서 ATRA는 fibroblast 에서 PI3K-Akt 신호 전달 체계를
억제하는 것으로 나타났다. 동물 실험에서 bleomycin 노출은 EphA2와
EphrinA1의 단백질 발현을 증가시켰다. ATRA의 투여는 lung injury 
score를 감소시키고 기관지폐포세척액의 단백질 농도를 감소시켰다. 
Bleomycin 비강 투여시 EphA2, EphrinA1 및 PI3K 110γ 단백의 발현이
증가하였으며, ATRA 투여 후 유의하게 감소하였다. IL-6와 TNF-α의
농도 또한 ATRA 그룹에서 bleomycin 그룹에 비하여 낮게 나타났다. 
EphA2 monoclonal antibody를 비강으로 투여하였을 때 폐섬유화가
감소하는 것으로 나타났으며, bleomycin 노출시 증가된 Wnt5a와 PI3K 
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단백은 EphA2 monoclonal antibody 그룹에서 유의하게 감소하는 것으로
나타났다. 
결론: 이상의 결과는 ATRA가 EphA2와 PI3K 신호 전달 체계를 통하여
bleomycin으로 유도된 폐 섬유화 모델에서 폐 섬유화를 감소시키고, 
또한, EphA2 수용체 억제제가 PI3K 신호 전달 체계와 ß-catenin 과는
독립적인 Wnt신호 전달 체계를 통하여 폐 섬유화를 감소시킴을 시사한다. 
ATRA와 EphA2 수용체 억제제의 폐 섬유화에 대한 약재로서의 잠재력을
확인하기 위한 추가적인 연구가 필요하다.  
-------------------------------------------------------------------
핵심되는 말: bleomycin, pulmonary fibrosis, All-trans retinoic acid, EphA2 
protein, PI3K, Wnt
